Skip to content
Conference Open access

Structural differences in the binding of Morphine and TRV130 agonists to the stability of µ-opioid receptor

Aug 2026 · Journal of Physics, Conference Series · Vol 3284 · 0 citations · 45 references
Physics

TL;DR

Computational investigation using molecular docking and molecular dynamics simulations is carried out to differentiate molecular mechanisms involved in the binding of morphine and oliceridine with the µOR receptor, showing that morphine forms persistent hydrogen bonds and electrostatic interactions, whereas TRV130 forms non-polar interactions with the orthosteric binding site of the receptor.

Abstract

Opioid agonists are drugs that bind primarily to the µ opioid (µOR) receptors in the central and peripheral nervous system to induce potent pain relief effects. Morphine is one of the most frequently used agonist for this purpose. However, it also causes several undesired side effects such as euphoria, depression, constipation, and drug addiction. This is because morphine can activate two intracellular signaling pathways: (i) the G protein signaling pathway responsible for pain relief; and (ii) β-arrestin recruitment responsible for the side effects. In this work, computational investigation using molecular docking and molecular dynamics simulations is carried out to differentiate molecular mechanisms involved in the binding of morphine (M6G, an unbiased agonist) and oliceridine (TRV130, a biased agonist that suppresses the second signaling pathway) with the µOR receptor. The results show that morphine forms persistent hydrogen bonds and electrostatic interactions, whereas TRV130 forms non-polar interactions with the orthosteric binding site of the receptor. As a result, M6G binding leads to a higher flexibility of the µOR’s transmembrane helix VII, in comparison with TRV130 binding, in qualitative agreement with studies on the β-arrestin recruitment by µOR receptor. Additionally, our investigation also indicates the allosteric effect of sodium ion. The ion binding pockets are different in different complexes and also different with unbound µOR receptor. Our finding contributes to a better pharmacology model for in-silico screening and discovery of biased opioids targeting µ opioid receptors.

Read PDF

Similar papers

Open access Aug 2026

Structure-guided allosteric modulation of the delta opioid receptor

Opioid analgesics remain essential for pain management but are associated with significant adverse effects, including respiratory depression, tolerance, and dependence. The δ-opioid receptor (δOR) represents a promising therapeutic target for developing safer opioid analgesics with reduced adverse effects compared to c...

J. Mobbs, M. D. Nguyen, Owindeep Deo et al. · 0 citations
Open access Aug 2026

The structure of the dopamine D3 receptor bound to cariprazine reveals principles for partial agonists with designed pharmacology

The third-generation antipsychotic cariprazine is a low-efficacy partial agonist of the dopamine D3 receptor (D3R). Here, we report the cryo–electron microscopy structure of cariprazine bound to D3R, establishing a framework for understanding ligand recognition in this receptor. We further determine structures of D3R i...

Eliane Hadas Yardeni, D. J. Kiss, Julie Sanchez et al. · 0 citations
Sep 2026

Two-Step Design of Triazole-Stapled Opioid Agonists Exhibiting Potent and Prolonged Peripheral Analgesic Activity.

This study establishes a two-step strategy for developing triazole-stapled multifunctional agonists that integrate opioid and neuropeptide FF (NPFF) pharmacophores. Initially, calcium mobilization assays, enzymatic stability tests, and analgesic activity screens identified triazole-stapled opioid peptide 16, derived fr...

Meng-Na Zhang, Jie Gao, Jia-Min Feng et al. · 0 citations
Review Open access Sep 2026

Opioid Peptide Hybrids as Multifunctional Analgesic Ligands: Emphasis on Intracellular Signaling

Opioid peptide hybrids are multifunctional molecules in which an opioid pharmacophore is covalently integrated with a second opioid or non-opioid pharmacophore within a single molecular entity. Their development is driven by a major challenge in analgesic pharmacotherapy: although μ-opioid receptor (MOR) agonists remai...

Igor Cecherz, Jakub Waśkiewicz, Alicja Dudek et al. · 0 citations
Sep 2026

Novel Allosteric Modulation of the Human 5-HT3A Receptor by the Clinically Used Drugs Piperazine and Hydroxyzine.

The 5-HT3 receptor is a serotonin-gated cation channel of the pentameric ligand-gated ion channel family and plays a key role in fast synaptic transmission within the central, peripheral, and enteric nervous systems. Dysregulation of this receptor has been linked to neurological, psychiatric, and gastrointestinal disor...

Noelia Rodriguez Araujo, J. Corradi, I. Bergé et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.